Redeye comments on AVTECH's Q1’23 report that showed slight negative sales deviation to estimates and better EBITDA than expected. AVTECH continues to show substantial operating leverage and is poised for solid growth in the coming quarters due to the recently signed agreement with Volaris.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/